Status:
COMPLETED
Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study proposes to compare 2 different methods for managing a subject with psoriasis who has achieved good disease control, as defined by a clinical response with a Physician Global Assessment (PG...
Eligibility Criteria
Inclusion
- Eighteen (18) years of age or older at the time of consent.
- Previously treated with etanercept for chronic plaque psoriasis for at least 12 weeks prior to the screening visit and received a total weekly dose of 50 mg per week for at least the 6 weeks preceding the day of the screening visit
- Having shown clinical response with a PGA inferior or equal to 1 at the screening visit.
- PGA inferior or equal to 1 at the baseline visit.
Exclusion
- Evidence of skin conditions (eg, eczema) other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis.
- Evidence of active or previously known medical history of inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis).
- Any biologics other than etanercept within the 20 weeks prior to the screening visit.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT00992394
Start Date
January 1 2010
End Date
April 1 2013
Last Update
January 8 2016
Active Locations (46)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hopitalier St Jacques (Place St Jacques)
Besançon, France, 25030
2
CHU Dupuytren
Limoges, France, 87042
3
Service de Chirurgie Infantile
Lyon, France, 69437
4
C.H.U Nantes
Nantes, France, 44093